Search

Forrest M. Phillips

Examiner (ID: 13425)

Most Active Art Unit
2837
Art Unit(s)
2837, 2832
Total Applications
2085
Issued Applications
1650
Pending Applications
115
Abandoned Applications
344

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 8779615 [patent_doc_number] => 20130101590 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-04-25 [patent_title] => 'BTNL9 PROTEINS, NUCLEIC ACIDS, AND ANTIBODIES AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 13/640232 [patent_app_country] => US [patent_app_date] => 2011-04-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 25548 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13640232 [rel_patent_id] =>[rel_patent_doc_number] =>)
13/640232
BTNL9 PROTEINS, NUCLEIC ACIDS, AND ANTIBODIES AND USES THEREOF Apr 7, 2011 Abandoned
Array ( [id] => 7566961 [patent_doc_number] => 20110287024 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-11-24 [patent_title] => 'VASCULAR ENDOTHELIAL CELL GROWTH FACTOR ANTAGONISTS' [patent_app_type] => utility [patent_app_number] => 13/053164 [patent_app_country] => US [patent_app_date] => 2011-03-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 11720 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0287/20110287024.pdf [firstpage_image] =>[orig_patent_app_number] => 13053164 [rel_patent_id] =>[rel_patent_doc_number] =>)
13/053164
VASCULAR ENDOTHELIAL CELL GROWTH FACTOR ANTAGONISTS Mar 20, 2011 Abandoned
Array ( [id] => 6101667 [patent_doc_number] => 20110165159 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-07-07 [patent_title] => 'USE OF CHIMERIC ANTI-CD20 ANTIBODY AS IN VITRO OR IN VIVO PURGING AGENT IN PATIENTS RECEIVING BMT OR PBSC TRANSPLANT' [patent_app_type] => utility [patent_app_number] => 13/051054 [patent_app_country] => US [patent_app_date] => 2011-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2724 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0165/20110165159.pdf [firstpage_image] =>[orig_patent_app_number] => 13051054 [rel_patent_id] =>[rel_patent_doc_number] =>)
13/051054
USE OF CHIMERIC ANTI-CD20 ANTIBODY AS IN VITRO OR IN VIVO PURGING AGENT IN PATIENTS RECEIVING BMT OR PBSC TRANSPLANT Mar 17, 2011 Abandoned
Array ( [id] => 10001464 [patent_doc_number] => 09045543 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-06-02 [patent_title] => 'Humanized anti-CD20 monoclonal antibody' [patent_app_type] => utility [patent_app_number] => 13/634072 [patent_app_country] => US [patent_app_date] => 2011-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 16 [patent_no_of_words] => 9235 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13634072 [rel_patent_id] =>[rel_patent_doc_number] =>)
13/634072
Humanized anti-CD20 monoclonal antibody Mar 15, 2011 Issued
Array ( [id] => 11547297 [patent_doc_number] => 09616120 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-04-11 [patent_title] => 'Monoclonal antibodies directed to CD20' [patent_app_type] => utility [patent_app_number] => 13/048135 [patent_app_country] => US [patent_app_date] => 2011-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16636 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13048135 [rel_patent_id] =>[rel_patent_doc_number] =>)
13/048135
Monoclonal antibodies directed to CD20 Mar 14, 2011 Issued
Array ( [id] => 6164721 [patent_doc_number] => 20110195023 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-08-11 [patent_title] => 'Internalizing Anti-CD74 Antibodies and Methods of Use' [patent_app_type] => utility [patent_app_number] => 13/047515 [patent_app_country] => US [patent_app_date] => 2011-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 22732 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0195/20110195023.pdf [firstpage_image] =>[orig_patent_app_number] => 13047515 [rel_patent_id] =>[rel_patent_doc_number] =>)
13/047515
Internalizing Anti-CD74 Antibodies and Methods of Use Mar 13, 2011 Abandoned
Array ( [id] => 6174258 [patent_doc_number] => 20110177067 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-07-21 [patent_title] => 'COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH INCREASED ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY (ADCC)' [patent_app_type] => utility [patent_app_number] => 13/042305 [patent_app_country] => US [patent_app_date] => 2011-03-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 11512 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0177/20110177067.pdf [firstpage_image] =>[orig_patent_app_number] => 13042305 [rel_patent_id] =>[rel_patent_doc_number] =>)
13/042305
COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH INCREASED ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY (ADCC) Mar 6, 2011 Abandoned
Array ( [id] => 6175866 [patent_doc_number] => 20110177526 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-07-21 [patent_title] => 'JANUS FAMILY KINASES AND IDENTIFICATION OF IMMUNE MODULATORS' [patent_app_type] => utility [patent_app_number] => 13/041204 [patent_app_country] => US [patent_app_date] => 2011-03-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11145 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0177/20110177526.pdf [firstpage_image] =>[orig_patent_app_number] => 13041204 [rel_patent_id] =>[rel_patent_doc_number] =>)
13/041204
JANUS FAMILY KINASES AND IDENTIFICATION OF IMMUNE MODULATORS Mar 3, 2011 Abandoned
Array ( [id] => 7487208 [patent_doc_number] => 20110236304 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-09-29 [patent_title] => 'STRUCTURAL VARIANTS OF ANTIBODIES FOR IMPROVED THERAPEUTIC CHARACTERISTICS' [patent_app_type] => utility [patent_app_number] => 13/037784 [patent_app_country] => US [patent_app_date] => 2011-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 39542 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0236/20110236304.pdf [firstpage_image] =>[orig_patent_app_number] => 13037784 [rel_patent_id] =>[rel_patent_doc_number] =>)
13/037784
STRUCTURAL VARIANTS OF ANTIBODIES FOR IMPROVED THERAPEUTIC CHARACTERISTICS Feb 28, 2011 Abandoned
Array ( [id] => 6080366 [patent_doc_number] => 20110142953 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-06-16 [patent_title] => 'COMBINATIONS OF IMMUNOSUPPRESSIVE AGENTS FOR THE TREATMENT OR PREVENTION OF GRAFT REJECTIONS' [patent_app_type] => utility [patent_app_number] => 13/025347 [patent_app_country] => US [patent_app_date] => 2011-02-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4853 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0142/20110142953.pdf [firstpage_image] =>[orig_patent_app_number] => 13025347 [rel_patent_id] =>[rel_patent_doc_number] =>)
13/025347
Combinations of immunosuppressive agents for the treatment or prevention of graft rejections Feb 10, 2011 Issued
Array ( [id] => 6164713 [patent_doc_number] => 20110195021 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-08-11 [patent_title] => 'CD20 ANTIBODIES AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 13/024556 [patent_app_country] => US [patent_app_date] => 2011-02-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 36 [patent_no_of_words] => 69323 [patent_no_of_claims] => 93 [patent_no_of_ind_claims] => 11 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0195/20110195021.pdf [firstpage_image] =>[orig_patent_app_number] => 13024556 [rel_patent_id] =>[rel_patent_doc_number] =>)
13/024556
CD20 antibodies and uses thereof Feb 9, 2011 Issued
Array ( [id] => 6164718 [patent_doc_number] => 20110195022 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-08-11 [patent_title] => 'CD20 ANTIBODIES AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 13/024671 [patent_app_country] => US [patent_app_date] => 2011-02-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 33 [patent_no_of_words] => 66384 [patent_no_of_claims] => 92 [patent_no_of_ind_claims] => 11 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0195/20110195022.pdf [firstpage_image] =>[orig_patent_app_number] => 13024671 [rel_patent_id] =>[rel_patent_doc_number] =>)
13/024671
CD20 antibodies and uses thereof Feb 9, 2011 Issued
Array ( [id] => 8054095 [patent_doc_number] => 20120076776 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-03-29 [patent_title] => 'METHOD FOR TREATING INFLAMATION BY LYMPHOCYTE DEPLETION OR SEQUESTERING' [patent_app_type] => utility [patent_app_number] => 13/021451 [patent_app_country] => US [patent_app_date] => 2011-02-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 31 [patent_no_of_words] => 11963 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0076/20120076776.pdf [firstpage_image] =>[orig_patent_app_number] => 13021451 [rel_patent_id] =>[rel_patent_doc_number] =>)
13/021451
METHOD FOR TREATING INFLAMATION BY LYMPHOCYTE DEPLETION OR SEQUESTERING Feb 3, 2011 Abandoned
Array ( [id] => 5969050 [patent_doc_number] => 20110150879 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-06-23 [patent_title] => 'SPECIFIC DEPLETION OF CD4+ T CELLS' [patent_app_type] => utility [patent_app_number] => 12/973375 [patent_app_country] => US [patent_app_date] => 2010-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 11420 [patent_no_of_claims] => 53 [patent_no_of_ind_claims] => 15 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0150/20110150879.pdf [firstpage_image] =>[orig_patent_app_number] => 12973375 [rel_patent_id] =>[rel_patent_doc_number] =>)
12/973375
SPECIFIC DEPLETION OF CD4+ T CELLS Dec 19, 2010 Abandoned
Array ( [id] => 7724442 [patent_doc_number] => 08097713 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2012-01-17 [patent_title] => 'Nucleic acid molecules which encode human anti-CD20 antibodies and methods of use thereof' [patent_app_type] => utility [patent_app_number] => 12/965956 [patent_app_country] => US [patent_app_date] => 2010-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 10855 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/08/097/08097713.pdf [firstpage_image] =>[orig_patent_app_number] => 12965956 [rel_patent_id] =>[rel_patent_doc_number] =>)
12/965956
Nucleic acid molecules which encode human anti-CD20 antibodies and methods of use thereof Dec 12, 2010 Issued
Array ( [id] => 8509182 [patent_doc_number] => 20120308590 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-12-06 [patent_title] => 'IMP-3 OLIGOPEPTIDES AND VACCINES INCLUDING THE SAME' [patent_app_type] => utility [patent_app_number] => 13/513120 [patent_app_country] => US [patent_app_date] => 2010-11-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 20756 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13513120 [rel_patent_id] =>[rel_patent_doc_number] =>)
13/513120
IMP-3 OLIGOPEPTIDES AND VACCINES INCLUDING THE SAME Nov 29, 2010 Abandoned
Array ( [id] => 6125291 [patent_doc_number] => 20110086004 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-04-14 [patent_title] => 'METHODS OF TREATING CANCER USING IL-21 AND MONOCLONAL ANTIBODY THERAPY' [patent_app_type] => utility [patent_app_number] => 12/947957 [patent_app_country] => US [patent_app_date] => 2010-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 25694 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0086/20110086004.pdf [firstpage_image] =>[orig_patent_app_number] => 12947957 [rel_patent_id] =>[rel_patent_doc_number] =>)
12/947957
METHODS OF TREATING CANCER USING IL-21 AND MONOCLONAL ANTIBODY THERAPY Nov 16, 2010 Abandoned
Array ( [id] => 6038434 [patent_doc_number] => 20110091483 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-04-21 [patent_title] => 'Canine Anti-CD20 Antibodies' [patent_app_type] => utility [patent_app_number] => 12/941583 [patent_app_country] => US [patent_app_date] => 2010-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 12939 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0091/20110091483.pdf [firstpage_image] =>[orig_patent_app_number] => 12941583 [rel_patent_id] =>[rel_patent_doc_number] =>)
12/941583
Canine anti-CD20 antibodies Nov 7, 2010 Issued
Array ( [id] => 6212367 [patent_doc_number] => 20110135667 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-06-09 [patent_title] => 'ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 12/940435 [patent_app_country] => US [patent_app_date] => 2010-11-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 44 [patent_figures_cnt] => 44 [patent_no_of_words] => 125826 [patent_no_of_claims] => 268 [patent_no_of_ind_claims] => 252 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0135/20110135667.pdf [firstpage_image] =>[orig_patent_app_number] => 12940435 [rel_patent_id] =>[rel_patent_doc_number] =>)
12/940435
Anti-CD79B antibodies and immunoconjugates and methods of use Nov 4, 2010 Issued
Array ( [id] => 5984647 [patent_doc_number] => 20110097344 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-04-28 [patent_title] => 'Compositions, Methods for Treatment, and Diagnoses of Autoimmunity-Related Disorders and Methods for Making Such Compositions' [patent_app_type] => utility [patent_app_number] => 12/910452 [patent_app_country] => US [patent_app_date] => 2010-10-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 23256 [patent_no_of_claims] => 46 [patent_no_of_ind_claims] => 29 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0097/20110097344.pdf [firstpage_image] =>[orig_patent_app_number] => 12910452 [rel_patent_id] =>[rel_patent_doc_number] =>)
12/910452
Compositions, Methods for Treatment, and Diagnoses of Autoimmunity-Related Disorders and Methods for Making Such Compositions Oct 21, 2010 Abandoned
Menu